Table 2 Use of antimicrobials in 2013 per production stage, reason for treatment; comparison with the 2010 data
Antibiotic usage in sows | Antibiotic usage in suckling piglets | Antibiotic usage in weaned piglets | Antibiotic usage in fattening pigs | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% nDD/an., 2013 | Evolution of nDD/an. 2010-2013 | % of using farms in 2010 and 2013 | % nDD/an., 2013 | Evolution of nDD/an., 2010-2013 | % of using farms in 2010 and 2013 | % nDD/an., 2013 | Evolution of nDD/an., 2010-2013 | % of using farms in 2010 and 2013 | % nDD/an., 2013 | Evolution of nDD/an., 2010-2013 | % of using farms in 2010 and 2013 | |||||
2010 | 2013 | 2010 | 2013 | 2010 | 2013 | 2010 | 2013 | |||||||||
Sample sizea (farm number) in 2010 and 2013 | 2010 = 91 - 2013 = 79 | 2010 = 91 - 2013 = 79 | 2010 = 122 - 2013 = 116 | 2010 = 160 - 2013 = 146 | ||||||||||||
Classes of antimicrobials | ||||||||||||||||
Aminosides | 2% | 0% | 36% | 38% | 7% | -39% | 27% | 29% | 6% | -23% | 44% | 47% | 4% | 40% | 25% | 21% |
Cephalosporins (3-4Gs) | 0% | -80% | 11% | 1% | 1% | -89% | 18% | 4% | 0% | 2% | 2% | 0% | 4% | 2% | ||
Fluoroquinolones | 4% | -34% | 53% | 57% | 8% | -36% | 44% | 41% | 0% | 60% | 32% | 23% | 1% | -25% | 24% | 19% |
Lincosamides | 0% | -25% | 8% | 9% | 3% | -63% | 5% | 4% | 3% | -51% | 32% | 21% | 10% | 264% | 17% | 13% |
Macrolides | 8% | 9% | 57% | 56% | 3% | -37% | 8% | 13% | 12% | -19% | 49% | 35% | 19% | -54% | 41% | 37% |
Polymyxins | 1% | -80% | 35% | 30% | 33% | -11% | 42% | 42% | 39% | -22% | 89% | 80% | 6% | -77% | 21% | 15% |
Penicillins | 8% | -27% | 81% | 82% | 38% | -21% | 64% | 65% | 6% | -8% | 66% | 60% | 5% | -14% | 61% | 49% |
TMP-sulphonamides | 22% | 39% | 20% | 18% | 2% | -72% | 4% | 4% | 22% | 59% | 27% | 24% | 15% | -30% | 14% | 12% |
Tetracyclines | 52% | 62% | 34% | 44% | 2% | 40% | 2% | 4% | 12% | -32% | 52% | 41% | 38% | 6% | 44% | 38% |
Sample sizeb | 2010 = 91 - 2013 = 79 | 2010 = 91 - 2013 = 79 | 2010 = 122 - 2013 = 116 | 2010 = 160 - 2013 = 146 | ||||||||||||
Pharmaceutical presentations | ||||||||||||||||
Injectable forms | 14% | 2% | 93% | 92% | 64% | -29% | 82% | 78% | 1% | -4% | 68% | 67% | 4% | 8% | 69% | 62% |
Oral powders, liquids and pastesb | 61% | 95% | 40% | 39% | 17% | 473% | 14% | 24% | 26% | 8% | 64% | 66% | 60% | 54% | 43% | 45% |
Medicated feed premixes | 24% | -36% | 24% | 18% | 19% | -59% | 14% | 6% | 74% | -25% | 84% | 73% | 36% | -64% | 29% | 16% |
Sample sizea | 2010 = 90 - 2013 = 74 | 2010 = 90 - 2013 = 79 | 2010 = 121 - 2013 = 107 | 2010 = 157 - 2013 = 141 | ||||||||||||
Indications for treatment | ||||||||||||||||
Digestive | 7% | 29% | 30% | 34% | 56% | -22% | 67% | 64% | 62% | -29% | 89% | 88% | 30% | -45% | 36% | 35% |
Locomotor | 3% | 150% | 29% | 64% | 37% | -17% | 56% | 58% | 1% | -78% | 28% | 51% | 1% | 33% | 35% | 45% |
Respiratory | 11% | 79% | 22% | 28% | 5% | 157% | 6% | 9% | 19% | -6% | 47% | 50% | 60% | -7% | 63% | 56% |
Systemic | 12% | 69% | 50% | 58% | 1% | -96% | 14% | 14% | 12% | 8% | 36% | 44% | 7% | -32% | 19% | 24% |
Genito-urinary | 65% | 17% | 70% | 70% | NAc | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Proportion of farms representing 50% of total usage | 2010 = 20% - 2013 = 13% | 2010 = 19% - 2013 = 14% | 2010 = 25% - 2013 = 18% | 2010 = 12% - 2013 = 8% | ||||||||||||